Abstract
Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high‐quality liver grafts are much needed. Direct‐acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV‐positive donors into HCV‐negative recipients. This review summarizes risk of transmission, treatment options with success rate, and ethical considerations for usage of HCV‐positive donors. Liver Transplantation 24 831–840 2018 AASLD.

This publication has 35 references indexed in Scilit: